{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:18:48Z","timestamp":1789154328364,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["Deutschland GmbH"],"award-info":[{"award-number":["Deutschland GmbH"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLSR13\/01"],"award-info":[{"award-number":["DJCLSR13\/01"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014841","name":"Medac","doi-asserted-by":"publisher","award":["Analysis of Anti-E.coli-ASNase"],"award-info":[{"award-number":["Analysis of Anti-E.coli-ASNase"]}],"id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014841","name":"Medac","doi-asserted-by":"publisher","award":["anti-PEG-ASNase antibodies"],"award-info":[{"award-number":["anti-PEG-ASNase antibodies"]}],"id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004869","name":"Universit\u00e4t M\u00fcnster","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13318-025-00962-3","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T12:03:59Z","timestamp":1755605039000},"page":"501-514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia Treated within the AIEOP-BFM ALL 2009 Trial: Population Pharmacokinetics and Drug Exposure"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7617-183X","authenticated-orcid":false,"given":"Gudrun","family":"W\u00fcrthwein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3518-9483","authenticated-orcid":false,"given":"Christian","family":"Siebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9764-8035","authenticated-orcid":false,"given":"Claudia","family":"Lanvers-Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3158-7484","authenticated-orcid":false,"given":"Petr","family":"Smisek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1013-3646","authenticated-orcid":false,"given":"Christa E.","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-1104","authenticated-orcid":false,"given":"Cristina","family":"Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-3893","authenticated-orcid":false,"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0034-5845","authenticated-orcid":false,"given":"Martin","family":"Schrappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-2025","authenticated-orcid":false,"given":"Joachim","family":"Boos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The AIEOP-BFM ALL 2009 Asparaginase Working Party","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"5","key":"962_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.v97.5.1211","volume":"97","author":"LB Silverman","year":"2001","unstructured":"Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91\u201301. Blood. 2001;97(5):1211\u20138. https:\/\/doi.org\/10.1182\/blood.v97.5.1211.","journal-title":"Blood"},{"issue":"3","key":"962_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.leu.2401310","volume":"13","author":"MD Amylon","year":"1999","unstructured":"Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335\u201342. https:\/\/doi.org\/10.1038\/sj.leu.2401310.","journal-title":"Leukemia"},{"issue":"2","key":"962_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00280-001-0391-5","volume":"49","author":"H-J M\u00fcller","year":"2002","unstructured":"M\u00fcller H-J, Beier R, da Palma JC, et al. PEG-asparaginase (Oncaspar) 2500 U\/m(2) BSA in reinduction and relapse treatment in the ALL\/NHL-BFM protocols. Cancer Chemother Pharmacol. 2002;49(2):149\u201354. https:\/\/doi.org\/10.1007\/s00280-001-0391-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"962_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00280-016-3236-y","volume":"79","author":"C Lanvers-Kaminsky","year":"2017","unstructured":"Lanvers-Kaminsky C. Asparaginase pharmacology: challenges still to be faced. Cancer Chemother Pharmacol. 2017;79(3):439\u201350. https:\/\/doi.org\/10.1007\/s00280-016-3236-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"962_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13318-021-00741-w","volume":"47","author":"C Siebel","year":"2022","unstructured":"Siebel C, Lanvers-Kaminsky C, Alten J, et al. Impact of antibodies against polyethylene glycol on the pharmacokinetics of PEGylated asparaginase in children with acute lymphoblastic leukaemia: a population pharmacokinetic approach. Eur J Drug Metab Pharmacokinet. 2022;47(2):187\u201398. https:\/\/doi.org\/10.1007\/s13318-021-00741-w.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"962_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13318-021-00670-8","volume":"46","author":"G W\u00fcrthwein","year":"2021","unstructured":"W\u00fcrthwein G, Lanvers-Kaminsky C, Siebel C, et al. Population pharmacokinetics of PEGylated asparaginase in children with acute lymphoblastic leukemia: treatment phase dependency and predictivity in case of missing data. Eur J Drug Metab Pharmacokinet. 2021;46:289\u2013300. https:\/\/doi.org\/10.1007\/s13318-021-00670-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"962_CR7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s13318-017-0410-5","volume":"42","author":"G W\u00fcrthwein","year":"2017","unstructured":"W\u00fcrthwein G, Lanvers-Kaminsky C, Hempel G, et al. Population pharmacokinetics to model the time-varying clearance of the PEGylated Asparaginase Oncaspar\u00ae in children with acute lymphoblastic leukemia. Eur J Drug Metab Pharmacokinet. 2017;42(6):955\u201363. https:\/\/doi.org\/10.1007\/s13318-017-0410-5.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"962_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/FTD.0000000000000472","volume":"40","author":"C Lanvers-Kaminsky","year":"2018","unstructured":"Lanvers-Kaminsky C, R\u00fcffer A, W\u00fcrthwein G, et al. Therapeutic drug monitoring of asparaginase activity-method comparison of MAAT and AHA test used in the international AIEOP-BFM ALL 2009 trial. Ther Drug Monit. 2018;40(1):93\u2013102. https:\/\/doi.org\/10.1097\/FTD.0000000000000472.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"962_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000893","volume":"7","author":"C Rizzari","year":"2023","unstructured":"Rizzari C, M\u00f6ricke A, Valsecchi MG, et al. Incidence and characteristics of hypersensitivity reactions to PEG-asparaginase observed in 6136 children with acute lymphoblastic leukemia enrolled in the AIEOP-BFM ALL 2009 study protocol. Hemasphere. 2023;7(6): e893. https:\/\/doi.org\/10.1097\/HS9.0000000000000893.","journal-title":"Hemasphere"},{"issue":"1","key":"962_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s0003-2697(02)00232-4","volume":"309","author":"C Lanvers","year":"2002","unstructured":"Lanvers C, Vieira Pinheiro JP, Hempel G, Wuerthwein G, Boos J. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem. 2002;309(1):117\u201326. https:\/\/doi.org\/10.1016\/s0003-2697(02)00232-4.","journal-title":"Anal Biochem"},{"issue":"1","key":"962_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3324\/haematol.2020.258525","volume":"107","author":"A Khalil","year":"2022","unstructured":"Khalil A, W\u00fcrthwein G, Golitsch J, et al. Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. Haematologica. 2022;107(1):49\u201357. https:\/\/doi.org\/10.3324\/haematol.2020.258525.","journal-title":"Haematologica"},{"issue":"13","key":"962_CR12","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","volume":"123","author":"WH Tong","year":"2014","unstructured":"Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123(13):2026\u201333. https:\/\/doi.org\/10.1182\/blood-2013-10-534347.","journal-title":"Blood"},{"key":"962_CR13","unstructured":"Icon Development Solutions. NONMEM users\u2019s guides: Ellicott City, Maryland, 2009."},{"issue":"17","key":"962_CR14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098. https:\/\/doi.org\/10.1056\/NEJM198710223171717.","journal-title":"N Engl J Med"},{"key":"962_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2021.11.016","volume":"162","author":"LJ Brigitha","year":"2022","unstructured":"Brigitha LJ, Fiocco M, Pieters R, et al. Hypersensitivity to pegylated E. coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group. Eur J Cancer. 2022;162:65\u201375. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.016.","journal-title":"Eur J Cancer"},{"key":"962_CR16","unstructured":"medac. Asparaginase-Aktivit\u00e4ts-Test (MAAT). Quantitativer Enzymtest zur Bestimmung der Asparaginase-Aktivit\u00e4t in Serum und EDTA-Plasma. Katalog-Nr.: 550 2018:550-VPD\/010418."},{"issue":"7","key":"962_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.19.02292","volume":"38","author":"RQH Kloos","year":"2020","unstructured":"Kloos RQH, Pieters R, Jumelet FMV, de Groot-Kruseman HA, van den Bos C, van der Sluis IM. Individualized asparaginase dosing in childhood acute lymphoblastic leukemia. J Clin Oncol. 2020;38(7):715\u201324. https:\/\/doi.org\/10.1200\/JCO.19.02292.","journal-title":"J Clin Oncol"},{"issue":"11 Pt 1","key":"962_CR18","first-page":"4554","volume":"41","author":"R Riccardi","year":"1981","unstructured":"Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 1981;41(11 Pt 1):4554\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"962_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/bjh.16495","volume":"190","author":"V Mondelaers","year":"2020","unstructured":"Mondelaers V, Ferster A, Uyttebroeck A, et al. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium. Br J Haematol. 2020;190(1):105\u201314. https:\/\/doi.org\/10.1111\/bjh.16495.","journal-title":"Br J Haematol"},{"issue":"5","key":"962_CR20","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2019.242289","volume":"106","author":"RQH Kloos","year":"2021","unstructured":"Kloos RQH, Math\u00f4t R, Pieters R, van der Sluis IM. Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. Haematologica. 2021;106(5):1254\u201361. https:\/\/doi.org\/10.3324\/haematol.2019.242289.","journal-title":"Haematologica"},{"issue":"4","key":"962_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41375-024-02153-6","volume":"38","author":"M Dam","year":"2024","unstructured":"Dam M, Centanni M, Friberg LE, et al. Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia. Leukemia. 2024;38(4):412\u2013719. https:\/\/doi.org\/10.1038\/s41375-024-02153-6.","journal-title":"Leukemia"},{"issue":"3","key":"962_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/bja\/aex007","volume":"118","author":"M Hara","year":"2017","unstructured":"Hara M, Masui K, Eleveld DJ, Struys MMRF, Uchida O. Predictive performance of eleven pharmacokinetic models for propofol infusion in children for long-duration anaesthesia. Br J Anaesth. 2017;118(3):415\u201323. https:\/\/doi.org\/10.1093\/bja\/aex007.","journal-title":"Br J Anaesth"},{"issue":"9","key":"962_CR23","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00228-020-02922-z","volume":"76","author":"YL Wang","year":"2020","unstructured":"Wang YL, Guilhaumou R, Blin O, Velly L, Marsot A. External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients. Eur J Clin Pharmacol. 2020;76(9):1281\u20139. https:\/\/doi.org\/10.1007\/s00228-020-02922-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"962_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s1470-2045(12)70600-9","volume":"14","author":"A Vora","year":"2013","unstructured":"Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199\u2013209. https:\/\/doi.org\/10.1016\/s1470-2045(12)70600-9.","journal-title":"Lancet Oncol"},{"issue":"22","key":"962_CR25","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/jco.2015.64.6364","volume":"34","author":"R Pieters","year":"2016","unstructured":"Pieters R, de Groot-Kruseman H, van der Velden V, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34(22):2591\u2013601. https:\/\/doi.org\/10.1200\/jco.2015.64.6364.","journal-title":"J Clin Oncol"},{"issue":"19","key":"962_CR26","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/jco.18.01877","volume":"37","author":"BK Albertsen","year":"2019","unstructured":"Albertsen BK, Grell K, Abrahamsson J, et al. Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study. J Clin Oncol. 2019;37(19):1638\u201346. https:\/\/doi.org\/10.1200\/jco.18.01877.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00962-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00962-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00962-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:11:03Z","timestamp":1761127863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00962-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00962-3","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"24 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The therapeutic drug monitoring program performed in the international AIEOP-BFM ALL 2009 trial has been in part supported by an unrestricted grant from the company Servier (and previously from medac GmBH, Sigma-Tau, Baxalta, and Shire, who have marketed the drug during the present study period). Analytical procedures have been supported by Servier Deutschland GmbH as well as medac GmbH. Anti-\n                      E. coli\n                      -ASNase and anti-PEG-ASNase antibodies have been analyzed by medac GmbH. Assay development and monitoring of anti-PEG antibodies within the AIEOP-BFM ALL 2009 trial was supported by Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung e.V. (DJCLSR 13\/01). Additional funding was provided by Servier Deutschland GmbH to perform the population pharmacokinetic analysis described here. Christa E. Nath is supported by the Cancer Centre for Children at The Children\u2019s Hospital at Westmead, Australia. Asparaginase monitoring in Australia was supported by funding from The Kids Cancer Alliance, a translational cancer research center of the Cancer Institute of New South Wales. No sources of funding were used to assist with the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C.L.K. held invited talks for Sigma tau, Erytech, Jazz Pharma, and Servier and received honoraria for consultancy from Erytech and a travel grant from Servier. C.R.\u2019s relationships with the companies Jazz Pharmaceuticals, Clinigen, and Servier marketing different asparaginase products have occurred throughout several years, in particular since when the study 2009 was started and was characterized by the introduction, in the clinical practice of the drug PEG-asparaginase as a first-line product and the Erwinia product as second line. The AIEOP-BFM ALL 2009 study was in any case an independent investigator-initiated study. The companies never interfered with his clinical, laboratory, and scientific activities regarding talks, or lectures or events when findings related to the abovementioned study were reported. M.S. and the ALL-BFM Study Center received funding from medac, Shire, Sigma-Tau, Servier, and Jazz Pharmaceuticals for research, and for functions in advisory boards. J.B. served personally as a consultant for the medac GmbH and Servier. He participated in advisory as well as on safety boards for the medac GmbH. He received support for travel from Eusa Pharma, Jazz Pharmaceuticals, Baxalta, Shire, and Servier. For medac GmbH, Eusa Pharma, Jazz Pharmaceuticals, Baxalta, Servier, Shire, and Sigma-Tau, he held invited lectures. For the Satellite meeting SIOP 2021, payment was to the university. In addition, institutional grants in the context of ASNase drug monitoring from more or less all ASNase providers contributed to the therapeutic drug monitoring program, including medac GmbH, Eusa Pharma, Jazz Pharmaceuticals, Baxalta, Servier, Shire, and Sigma-Tau (all representing the varying marketing authorization holders of\n                      E. coli\n                      ASNase, PEG-ASNase, and Erwinase).CS, CM, PS, CN and GW declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests"}},{"value":"The data sets generated and\/or analyzed during the current study are not publicly available due to data protection rules and the fact that the complexity of the data does not allow for full anonymization.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The AIEOP-BFM ALL 2009 trial (EudraCT No: 2007-004270-43) was approved by each national and local review board and was conducted in accordance with the Declaration of Helsinki and applicable national legislation. Informed consent was obtained from the parents or guardians of each patient included in the study. As the analysis described here extended the original informed consent, an additional ethics committee vote was obtained (Ethics Committee of the Medical Association Westfalen-Lippe and the University of M\u00fcnster; reference number 2021-071-f-S).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from the parents or legal representative of each patient included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The NONMEM codes for the final popPK models are provided on request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"C.S., G.W., C.L.K., and J.B. designed the research. C.M., C.R., C.N., P.S., and M.S. collected the data. C.S., G.W., C.L.K., and J.B. performed and discussed the pharmacokinetic analysis. Results were discussed and interpreted by all authors during scientific meetings of the Asparaginase Working Party. G.W. and J.B. wrote the manuscript; all authors reviewed the manuscript and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}